VINORELBINE PIERRE FABRE vinorelbine 50mg/5mL (as tartrate) injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Commercializzato da:

Pierre Fabre Australia Pty Ltd

Forma farmaceutica:

Injection, concentrated

Composizione:

Excipient Ingredients: water for injections

Via di somministrazione:

Intravenous

Confezione:

1 x 5mL, 10 x 5mL

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.

Dettagli prodotto:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2000-08-04